Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture:Final Results of a 78-Week Randomized Clinical Trial by Malouf-Sierra, Jorge et al.
Syddansk Universitet
Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric
Hip Fracture
Final Results of a 78-Week Randomized Clinical Trial
Malouf-Sierra, Jorge; Tarantino, Umberto; García-Hernández, Pedro A; Corradini, Costantino;
Overgaard, Soren; Stepan, Jan J; Borris, Lars; Lespessailles, Eric; Frihagen, Frede;
Papavasiliou, Kyriakos; Petto, Helmut; Aspenberg, Per; Caeiro, José Ramón; Marin,
Fernando
Published in:






Publisher's PDF, also known as Version of record
Document license
Unspecified
Citation for pulished version (APA):
Malouf-Sierra, J., Tarantino, U., García-Hernández, P. A., Corradini, C., Overgaard, S., Stepan, J. J., ... Marin,
F. (2017). Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture:
Final Results of a 78-Week Randomized Clinical Trial. Journal of Bone and Mineral Research, 32(5),
1040–1051. DOI: 10.1002/jbmr.3067
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
Effect of Teriparatide or Risedronate in Elderly Patients
With a Recent Pertrochanteric Hip Fracture: Final Results
of a 78-Week Randomized Clinical Trial
Jorge Malouf-Sierra,1 Umberto Tarantino,2 Pedro A Garcıa-Hernandez,3 Costantino Corradini,4
Søren Overgaard,5 Jan J Stepan,6 Lars Borris,7 Eric Lespessailles,8,9 Frede Frihagen,10 Kyriakos Papavasiliou,11
Helmut Petto,12 Per Aspenberg,13 Jose Ramon Caeiro,14 and Fernando Marin15
1Internal Medicine, Hospital San Pablo, Barcelona, Spain
2Orthopaedic Surgery, University Tor Vergata, Rome, Italy
3Osteoporosis Center, University Hospital, Monterrey, Mexico
4Department of Biomedical Surgical and Dental Sciences, University of Milan, c/o 1st University Division of Orthopaedy and Traumatology, ASST
Gaetano Pini, Milan, Italy
5Department of Orthopaedic Surgery and Traumatology, Odense University Hospital Institute of Clinical Research, University of Southern Denmark,
Odense, Denmark
6Institute of Rheumatology and Faculty of Medicine, Charles University, Prague, Czech Republic
7Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark
8Institut de prevention et de recherche sur l’osteoporose (IPROS), Department of Rheumatology, Centre Hospitalier Regional (CHR) d’Orleans,
Orleans, France
9Imagerie Multimodale Multiechelle et Modelisation du Tissu Osseux (I3MTO), EA 4708, Orleans University, Orleans, France
10Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway
113rd Orthopaedic Department, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece
12Eli Lilly, Vienna, Austria
13Department of Clinical and Experimental Medicine, Link€oping University, Link€oping, Sweden
14Department of Orthopaedic Surgery and Traumatology, Santiago de Compostela University Hospital, Health Research Institute, University of
Santiago de Compostela, Santiago de Compostela, Spain
15Eli Lilly Research Centre Ltd, Erl Wood Manor, Surrey, UK
ABSTRACT
We present ﬁnal results of a study comparing teriparatide 20mg every day (QD) with risedronate 35mg once per week (QW) started
within 2 weeks after surgery for a pertrochanteric hip fracture. Patients with BMD T-score –2.0 and 25OHD 9.2 ng/mL were
randomized to receive 26-weekdouble-dummy treatment plus calciumandvitaminD, followedby52-weekopen-label treatmentwith
the same assigned active drug. Primary endpoint was change from baseline in lumbar spine (LS) BMD at 78 weeks. Secondary and
exploratory endpoints were change in BMD at the proximal femur, function, hip pain (Charnley score and 100mmVisual Analog Scale
[VAS]), quality of life (Short Form-36), radiology outcomes, and safety. Data were analyzed with mixed models for repeated measures
(MMRM) and logistic regression. Totally, 224 patients were randomized; 171 (teriparatide: 86) contributed to the efﬁcacy analyses
(mean SD age: 77 7.7 years, 77% females). Mean baseline LS, femoral neck (FN), and total hip (TH) T-scores were –2.16, –2.63, and
–2.51, respectively. At 78weeks, BMD increased signiﬁcantlymorewith teriparatide compared to risedronate at the LS (þ11.08%versus
þ6.45%; p< 0.001) and FN (þ1.96% versus –1.19%; p¼ 0.003), with no signiﬁcant between-group difference in TH BMD. Timed up-
and-go (TUG) test was signiﬁcantly faster with teriparatide at 6, 12, 18, and 26 weeks (differences: –3.2 to –5.9 s; p¼ 0.045 for overall
difference). Hip pain during TUG test by 100mm VAS was signiﬁcantly lower with teriparatide at 18 weeks (adjusted difference:
–11.3mm, p¼ 0.033; –10.0 and –9.3mm at 12 and 26 weeks, respectively; p¼ 0.079 for overall difference). Other secondary and
exploratory outcomes were not different. Teriparatide group showed two new hip fractures versus seven with risedronate (p¼ 0.171)
andmore frequent hypercalcemia and hyperuricemia. In conclusion, 78-week treatmentwith teriparatide showed signiﬁcantly greater
increases in LS andFNBMD, less pain, anda faster TUG test versus risedronate. © 2016American Society for Bone andMineral Research.
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Introduction
Hip fracture is themost devastating outcome associatedwithosteoporosis. This fracture causes pain, disability, dimin-
ished quality of life, and premature mortality. It is also a growing
health problem, as it has been estimated that, worldwide, the
number of hip fractures will approximately double to 2.6 million
by the year 2025, and 4.5 million by the year 2050.(1) Moreover,
patients with a hip fracture have a fourfold to eightfold
increased risk of further fracturing at another site.(2) The risk of
mortality is increased approximately twofold during the ﬁrst
postfracture year, after which it decreases(3); however, there
remains an excess risk of mortality 5 to 10 years after the hip
fracture.(4) This excess mortality is more pronounced among
individuals having lower BMD values(5) and some data suggest
that osteoporosis is a risk factor for long-term mortality in hip
fracture.(6)
In spite of the new technical improvements in internal
ﬁxation, patients with hip and lower limb fractures have reduced
physical activity and variable periods of limited mobility during
the weeks or months after the fracture. The consequent absence
of weight bearing leads to bone loss at several sites,(7–12) more
notably at the contralateral, unfractured hip, where it can
decrease approximately by 5% during the ﬁrst year after the
fracture.(13–16) Bone loss starts immediately after fracture but can
be detected several years later.(9,17) This additional and rapid
bone loss after fracture of a weight-bearing bone substantially
increases the risk for subsequent fragility fractures.(18–20)
Thus, to preserve the bone density and for other reasons,
elderly patients with hip fractures need to be mobilized as
quickly as possible. Interventions to prevent bone loss
associated with reduced mobilization after a hip fracture are
needed, especially in patients who have reduced bone mass
before the fracture occurs.
Previous investigations demonstrated an effect of bisphosph-
onates in the prevention of lower limb immobilization-related
BMD loss.(11,21,22) Teriparatide, administered by daily s.c. injec-
tion, activates osteoblasts and stimulates the formation of new
bone and, thereby, increases bone mass and bone strength,(23)
effectively reducing vertebral and nonvertebral fractures in
postmenopausal women with severe osteoporosis.(24) However,
there are no controlled studies in humans analyzing the effects
of teriparatide on BMD in patients who are exposed to a certain
degree of immobilization. Pivotal teriparatide clinical trials
excluded patients whowere not ambulatory. Furthermore, there
are some conﬂicting results in studies regarding PTH treatment
during conditions of disuse. Some studies suggest that PTH is
able to reduce bone loss resulting from disuse,(25–28) whereas
other studies show that the bone anabolic effect of PTH is
attenuated if mechanical loading is absent.(29–31) Moreover,
some authors have raised concerns that the increase in
intracortical remodeling induced by teriparatide may reduce
the hip strength, predisposing patients to second fractures.(32)
We performed an active controlled study to evaluate whether
teriparatide was superior to risedronate in the change in lumbar
spine BMD from baseline to 78 weeks after a recent
pertrochanteric fracture of the hip (primary objective), the
hypothesis being that a bone anabolic drug will show better
effects than an anti-remodeling drug. Results from a preplanned
analysis of secondary non-BMD–related, fracture recovery–
related outcomes at 26 weeks were reported earlier, and
showed that teriparatide was associated with less hip pain and a
shorter time to complete the timed up-and-go (TUG) test.(33)
Here, we present ﬁnal results of the efﬁcacy and safety analyses
after patients completed the full 78 weeks of treatment.
Patients and Methods
Study design
Thismultinational, multicenter, prospective, randomized, active-
controlled study was conducted from April 2009 to August 2015
across 17 countries in North America, Mexico, and Europe. It
included three study periods: (1) a screening phase of up to
14 days from the day of surgery to the day of randomization; (2) a
double-blind, double-dummy treatment phase from the time of
randomization to the 26-week visit; and (3) an open-label
treatment phase where patients continued treatment up to
78 weeks with the same study drug to which they were
randomized.
The study includedmenandpostmenopausalwomenwith low
bonemass who had sustained a recent unilateral pertrochanteric
fracture (Arbeitsgemeinschaft f€ur Osteosynthesefragen [AO]/
Orthopaedic Trauma Association [OTA] types 31-A1 and 31-A2)
and were treated with osteosynthesis with a sliding compression
hip screw or a trochanteric intramedullary nail. Low bone mass
was deﬁned by a BMD T-score –2.0 SDs at the total hip, femoral
neck, or lumbar spine. Hospital-based physicianswith experience
in treating hip fractures screened over 2400 patients and enrolled
389 patients who met the eligibility criteria. The key eligibility
criteria and reasons for exclusion during screening are summa-
rized in Aspenberg and colleagues.(33)
During the screening period, all patients were started on oral
supplements with elemental calcium (500 to 1000mg/day) and
vitamin D (approximately 800 IU/day). Those with serum 25OHD
level between 9.2 and 16 ng/mL received an oral loading dose of
100,000 IU of vitamin D2 or D3.
Eligible patients were randomly assigned, within 2 weeks of
osteosynthesis, in a 1:1 ratio to teriparatide 20mg subcutaneous
injection once daily plus oral placebo once weekly or placebo
subcutaneous injection once daily plus oral risedronate 35mg
onceweekly for 26 weeks. Treatment assignment was blinded to
patients, investigators, and relevant staff; stratiﬁed by type of
fracture; and determined by a computer-generated random
sequence. At the 26-week visit, the treatment was unblinded
and patients continued for an additional 52weekswith the same
treatment towhich theywere randomized for a total of 78weeks
continuous treatment. Patients were not permitted to take any
other antiosteoporosis medication during the study period.
Treatment compliance was assessed by direct questioning
and quantifying the study materials returned at scheduled
visits. A patient who missed more than 25% of the injectable
or oral study drug in two consecutive visits was considered
noncompliant.
Outcomes
Primary and secondary BMD-related outcomes
The primary efﬁcacy outcome was the change in lumbar spine
BMD from baseline to 78 weeks. Changes in lumbar spine BMD
from baseline to 26 and 52 weeks, and changes in femoral neck
and total hip BMD from baseline to 26, 52, and 78 weeks were
secondary efﬁcacy outcomes. BMDwas assessed by dual-energy
X-ray absorptiometry (DXA) using either Hologic or Lunar
equipment; systematic differences between the equipment
were reconciled with a cross-calibration adjustment method.
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There were no changes in the DXA scanners during the study at
any of the participant study sites. All bone density scans were
evaluated centrally by two independent readers blinded to
treatment assignment (Synarc Inc., Hamburg, Germany).
Functional and patient-reported outcomes
Functional outcomes included: (1) functional mobility, evalu-
ated with the TUG test(34,35); (2) self-reported hip pain, assessed
with a 100-mm linear Visual Analog Scale (VAS)(36) and a
modiﬁed Charnley pain score(37); and (3) patient-reported
health status, estimated with the self-administered Short
Form-36 (SF-36) survey.(37–40) For a detailed description of the
fracture recovery outcomes, see Aspenberg and colleagues.(33)
Functional outcomes were assessed as secondary endpoints up
to the 26-week visit, and as exploratory endpoints at 52 and
78 weeks.
Recovery of the ability to walk and use of walking aids were
assessed as exploratory endpoints at all postbaseline visits.
Ability to walk was evaluated with a classiﬁcation based on the
standard deﬁnitions of community and household ambula-
tion.(41) Detailed information on the categories of walking aids
used was also collected.(33)
Functional and patient-reported outcomes were assessed
in the following order at each postbaseline visit: (1) SF-36
survey; (2) TUG test; (3) hip pain assessment by 100mm VAS;
(4) modiﬁed Charnley hip pain score; and (5) ability to walk.
Radiological outcomes
These were exploratory outcomes and included radiological
evidence of fracture healing, frequency of nonunion, and
mechanical failure of the implant. The criteria for deﬁning these
outcomes have been described.(33) Radiological healing was
evaluated at 6, 12, and 26 weeks by assessing the features of
cortical bridging, disappearance of the fracture line, and
progressive sclerosis of the fracture line on conventional
anteroposterior and lateral radiographs. In addition, the
presence of fracture nonunion and potential mechanical failure
of the implant was analyzed at 26 weeks and at the ﬁnal or early
discontinuation visit. X-ray images of the hip were centrally
adjudicated by two independent radiologists who were blinded
to treatment assignment (Synarc Inc.).
Safety
Safety was analyzed in all patients who received at least one
dose of study medication. Analyses included treatment-
emergent adverse events (TEAEs); incident clinical fractures;
analgesic use for hip pain; serum levels of 25OHD, calcium and
uric acid; clinical chemistry and hematology; and vital signs.
Statistical methods
Sample size estimation was based on the primary outcome; ie,
change in lumbar spine BMD after 78 weeks of treatment. A
difference of 0.023 g/cm2 and a common SD of 0.047 in each
group were expected after treatment for 78 weeks. To detect a
difference between treatments with 85%power and a two-sided
statistical signiﬁcance of 0.05, it was planned to enroll 76
patients in each group. Allowing for a 30% dropout, this number
was increased to 109 for each group.
Efﬁcacy analyses were conducted on the full analysis set (FAS),
which follows the intent-to-treat principle. The FAS included all
randomized patients receiving at least one dose of the study
drug and with at least one follow-up efﬁcacy measure. Safety
analyses were conducted on all patients who received at least
one dose of study drug.
Descriptive statistics were used to summarize baseline patient
characteristics in the treatment groups and overall population.
The primary efﬁcacy analysis was a mixed models for repeated
measures (MMRM) analysis, which included treatment, visit,
treatment-by-visit interaction, fracture type, and baseline BMD
as ﬁxed effects. MMRM accounts for data missing at random by
using the correlation of observations within each patient and
without the need of any explicit imputations.(42) In addition, a
“full model” was constructed by individually adding predeﬁned
ﬁxed effects (age, gender, duration of prior bisphosphonates,
and use of glucocorticoids at baseline) to the primary model.
Charnley hip pain score and radiological outcomes were
analyzed with logistic regression with repeated measures to
model the probability of a positive outcome. At each follow-up
visit, covariate-adjusted (least squares [LS]) mean changes from
baseline with SEs were derived from MMRM and logistic
regression for the two treatments, and p values and 95% CIs
were reported for their differences. Frequencies of patients
experiencing TEAEs, new clinical fractures, and abnormal
laboratory parameters were compared between treatments
using Fisher’s exact test. Level of signiﬁcance for tests was set
to p< 0.05 (without multiplicity adjustments). All data were
analyzed using SAS software version 9.4 (SAS Institute, Inc., Cary,
NC, USA).
Due to the statistical analysis method of MMRM applied to the
efﬁcacy data and the additional time points at 52 and 78 weeks
for functional and patient-reported outcomes, 26-week analysis
results as reported in Aspenberg and colleagues(33) vary slightly
compared with the results after completing 78 weeks of
treatment presented in this manuscript. The 26-week analysis
should be considered the primary one for the functional
outcomes based on MMRM because it included more cases and
was restricted to the double-dummy phase.
The study was approved by institutional review boards at
each center, and conducted in accordance with the ethical
principles of the Declaration of Helsinki, good clinical practices,
and applicable laws and regulations. All patients provided
written informed consent before undergoing any screening
procedures. The study was funded by Eli Lilly and Company
(ClinicalTrials.gov Identiﬁer: NCT00887354). The sponsor
designed the protocol with advice from external advisors (PA,
JRC), and was responsible for the quality control of data
collected and the statistical analyses.
Results
Of the 389 screen patients, 224 patients were randomized, and
171 were included in the FAS (Fig. 1). The most frequent reason
for screen failures (47.3% of the non-eligible patients) was BMD
above –2.0 SD at all measured sites, followed by secondary
hyperparathyroidism (26.7%) and severe vitamin D deﬁciency
(14.5%). A total of 118 patients (52.7%) completed the full
78-week study duration (Fig. 1).
Baseline characteristics of the study patients were balanced
between treatment groups and were described in detail by
Aspenberg and colleagues.(33) In summary, the mean SD age
was 76.8 7.7 years and 77.2% of the patients were females
(Table 1). There were no differences in the frequencies of
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common comorbidities between groups (Supporting Table 1).
At baseline, the mean SD BMD measured at the lumbar spine,
total hip and femoral neck ranged from 0.602 0.107 to
0.862 0.170 g/cm2 in the overall population (Table 1). Only
13.5% of the patients reported any previous pharmacological
treatment for osteoporosis, and 25.7% reported a previous
history of low-trauma fracture after the age of 50 years. Median
(interquartile range [IQR]) time from hip fracture to administra-
tion of the ﬁrst treatment dose was 15 days (IQR, 12 to 18 days).
The median durations of teriparatide and risedronate treatment
were 545 and 548 days, respectively. The overall median
(IQR) daily supplemental doses of calcium and vitamin D were
800mg (IQR, 500 to 1000mg), and 800 IU (IQR, 800 to 850 IU),
respectively.
Fig. 1. Flowchart of enrolled patients. Note: One patient who discontinued due to patient decision and another who discontinued due to death (both of
the risedronate group) were double-counted in the summary of discontinuations by reason betweenWeek 26 andWeek 78. aTwo enrolled patients were
not screen failures but were not randomized. bIncluding two patients who discontinued after completing Week 26 visit. cIncluding three patients who
discontinued after completing Week 26 visit. N¼ total number of patients.
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Primary and secondary BMD-related outcomes
Treatment with teriparatide was superior to risedronate in
the change of lumbar spine BMD from baseline to Week 78 (LS
mean difference, 0.040 g/cm2; 95% CI, 0.025 to 0.055 g/cm2;
p< 0.0001; Fig. 2). Thus, the primary objective of the study was
achieved. Furthermore, the LS mean change in BMD was
signiﬁcantly greater in the teriparatide group at Week 26 (LS
mean difference, 0.020 g/cm2; 95% CI, 0.006 to 0.035 g/cm2;
p¼ 0.007; Fig. 2) and Week 52 (0.034 g/cm2; 95% CI, 0.019 to
0.049g/cm2; p< 0.0001; Fig. 2).
At Week 78, femoral neck BMD increased signiﬁcantly versus
baseline with teriparatide, while it decreased with risedronate,
leading to a signiﬁcant LS mean difference in BMD between
treatments of 0.019 g/cm2 (95% CI, 0.006 to 0.031 g/cm2;
p¼ 0.003) (Fig. 3). The treatment difference was not statistically
signiﬁcant at earlier time points (Fig. 3).
There was no signiﬁcant difference between treatments for
the change in total hip BMD from baseline to any of the time
points (Fig. 4).
Functional and patient-reported outcomes
As previously reported in the analysis of the double-dummy
phase of the trial,(33) the time required to complete the TUG
test was signiﬁcantly shorter with teriparatide versus risedr-
onate at Week 6 (LS mean time, 26.5 versus 32.4 s, p¼ 0.016),
Week 12 (20.1 versus 24.5 s, p¼ 0.021), Week 18 (17.8 versus
21.1 s, p¼ 0.042), and Week 26 (16.7 versus 19.9 s, p¼ 0.040).
There was no signiﬁcant difference between treatments at
Week 52 or Week 78 (Fig. 5; Supporting Table 2).
Hip pain during the TUG test assessed by VAS was lower with
teriparatide versus risedronate at Week 18 (signiﬁcant adjusted
absolute difference: –11.3mm; 95% CI, –21.65 to –0.94;
p¼ 0.033), and 12 and 26 weeks (–10.0mm, p¼ 0.056; and
–9.3mm, p¼ 0.079). There was no signiﬁcant difference
between treatments at Week 52 or Week 78 (Fig. 6; Supporting
Table 3).
There were no signiﬁcant differences between treatments for
patient–reported health status assessed by SF-36 (Supporting
Table 4) or self-reported hip pain by the Charnley pain score at
any of the time points (data not shown).
There were no signiﬁcant differences between treatments
for the ability to walk (ambulatory category) or the use of
different walking aids at any of the follow-up visits (data not
shown).
By the 78-week visit, patients were predominantly in the
ambulatory category, with only two of 57patients in the
teriparatide group and one of 59 in the risedronate group in
a nonfunctional ambulatory status (p¼ 0.589).
Radiological outcomes
Radiological healing (ie, stable fracture alignment and radio-
graphic union) was achieved by all study patients byWeek 26,(33)
Table 1. Baseline Characteristics
Teriparatide (n¼ 86) Risedronate (n¼ 85) Total (n¼ 171)
Age (years), mean SD 77.2 8.0 76.4 7.5 76.8 7.7
Gender, n (%)
Female 66 (76.7) 66 (77.6) 132 (77.2)
Male 20 (23.3) 19 (22.4) 39 (22.8)
Prior osteoporosis drug use, n (%)
1 osteoporosis drug 12 (14.0) 11 (12.9) 23 (13.5)
1 bisphosphonatea 7 (8.1) 9 (10.6) 16 (9.4)
Other osteoporosis drugsb 6 (7.0) 3 (3.5) 9 (5.3)
Duration of prior bisphosphonate use (months), median (IQR) 65.6 (38.078.8) 24.4 (5.142.8) 40.4 (10.474.8)
Glucocorticoid use during the study, n (%) 13 (12.3) 7 (6.4) 20 (9.3)
Vitamin D megadose before randomization, n (%)c 12 (14.0) 21 (24.7) 33 (19.3)
Patients with >1 fractures occurring between age 50 years and study entry, n (%)
All fractures 37 (43.0) 30 (35.3) 67 (39.2)
Low-trauma fractures 27 (31.4) 17 (20.0) 44 (25.7)
Type of fracture, n (%)d
31-A1 39 (45.3) 46 (54.1) 85 (49.7)
31-A2 47 (54.7) 38 (44.7) 85 (49.7)
Other (intracapsular) 0 1 (1.2) 1 (0.6)
Areal density (g/cm2), mean SD
Lumbar spine BMD 0.873 0.176 0.850 0.163 0.862 0.170
Femoral neck BMD 0.603 0.098 0.602 0.116 0.602 0.107
Total hip BMD 0.670 0.098 0.672 0.113 0.671 0.106
T-score, mean SD
Lumbar spine BMD –2.03 1.470 –2.28 1.239 –2.16 1.360
Femoral neck BMD –2.63 0.519 –2.63 0.657 –2.63 0.591
Total hip BMD –2.52 0.692 –2.49 0.790 –2.51 0.741
Percentages are based on number of patients with nonmissing values. Patients in the full analysis set are included.
IQR¼ interquartile range.
aAlendronate, risedronate, or ibandronate.
bOther osteoporosis drugs included calcium and/or vitamin D, calcitonin, selective estrogen receptor modulators, and vitamin D active metabolites.
cA vitamin D megadose was administered in patients with 25OHD levels between 9.2 and 16 ng/mL at baseline.
dAs determined by the central reader.
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except one patient in the risedronate group who achieved it by
Week 78. At Week 26, there was no signiﬁcant difference
between treatments for the frequency of loss of reduction or
mechanical failure of the implant.(33) At Week 78, mechanical
failure of the implant was observed in one additional patient in
the risedronate group (teriparatide: 7 [13.0%]; risedronate: 9
[15.5%]; p¼ 0.386). The predominant cause of implant failure
was excessive progression of offset in both treatment groups,
Fig. 2. Change from baseline in lumbar spine BMD (FASa). aMMRM analysis; predeﬁned variables in the full model included treatment, visit, treatment-
by-visit interaction, type of fracture (31-A1, 31-A2), baseline lumbar spine BMD, and glucocorticoid use at baseline. p¼ 0.007 and #p< 0.0001 versus
risedronate; p< 0.0001 versus baseline for both groups at all time points. FAS¼ full analysis set; LS¼ least squares.
Fig. 3. Change from baseline in femoral neck BMD (FASa). aMMRM
analysis; predeﬁned variables in the full model included treatment, visit,
treatment-by-visit interaction, type of fracture (31-A1, 31-A2), and
baseline femoral neck BMD. p¼ 0.035 compared to baseline;
#p¼ 0.0098 compared to baseline; &p¼ 0.003 versus risedronate.
FAS¼ full analysis set; LS¼ least squares.
Fig. 4. Change from baseline in total hip BMD (FASa). aMMRM analysis;
predeﬁned variables in the full model included treatment, baseline total
hip BMD, visit, type of fracture (31-A1, 31-A2), treatment-by-visit
interaction, and duration of prior bisphosphonate therapy. No signiﬁcant
changes betweengroups or compared tobaseline for any of the treatment
groups at any time point. FAS¼ full analysis set; LS¼ least squares.
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with only one patient in each treatment group showing lag
screw cutout. Loss of reduction was observed in two (3.2%) and
four (6.5%) patients in the teriparatide and risedronate groups,
respectively (p¼ 0.440); all cases occurred during the ﬁrst
26 weeks of follow-up. There were no cases of nonunion in the
study cohort.
Safety
Treatment compliance was similar in the two treatment groups
(98.6% in the teriparatide group and 98.4% in the risedronate
group). The frequencies of deaths, serious adverse events
leading to hospitalization, and clinical fractures were higher with
risedronate than with teriparatide, but the difference was not
statistically signiﬁcant (Table 2). There were ﬁve new fractures in
the teriparatide group and 12 in the risedronate group
(p¼ 0.099), including two and seven new hip fractures,
respectively (p¼ 0.171). The overall analgesic use at 78 weeks
was 19.4%, with no signiﬁcant difference between treatment
groups (p¼ 0.848). Patients receiving teriparatide showed
signiﬁcantly higher serum alkaline phosphatase levels versus
risedronate at Week 26 (p¼ 0.010) and Week 78 (p¼ 0.002).
Hyperuricemia and hypercalcemia were more frequent with
teriparatide than risedronate at 6-week and 26-week follow-up
visits, respectively (Table 2). Hypercalcemia associated with
teriparatide was generally mild with eight of the 15 patients
having a maximum albumin-corrected, postbaseline serum
calcium level 2.70mmol/L (Supporting Table 5). Mean serum
levels of 25OHD were approximately 10 pmol/mL (4 ng/mL)
signiﬁcantly lower in the teriparatide group at Week 26 and
Week 78, but remained above 50 pmol/mL (20 ng/mL) in the
study cohort (Table 2).
Other laboratory parameters and vital signs were not
signiﬁcantly different between the two treatment groups at
any time points.
Discussion
Patients with hip fracture represent an important population to
target for the prevention of secondary fractures because they
are at an increased risk of recurrent fragility fractures. For
instance, the reported incidence of a second hip fracture was
between 4% and 9% after 1 year of the ﬁrst hip fracture.(43–46)
Furthermore, these patients have two to three times higher risk
of fracture at other (non-hip) sites compared with the expected
fracture rate in the general population.(2,47) However, the care of
patients after hip fracture has been suboptimal. Less than one-
third of patients suffering a hip fracture receive subsequent
osteoporosis treatment,(48,49) and with no trend toward
improvement over time in several countries.(50) Although
evidence from randomized clinical trials does not show adverse
effects on fracture healing in patients treated with bisphosph-
onates shortly after surgical repair of a hip fracture,(51,52)
physicians hesitate to initiate osteoporosis treatment upon
discharge after a surgery for hip fracture.
In our study, treatment with 78 weeks of teriparatide showed
signiﬁcantly greater increases in lumbar spine and femoral neck
BMD of the contralateral unfractured hip compared with
risedronate. The increase in lumbar spine BMD was also
signiﬁcantly greater versus risedronate after 26 and 58 weeks
of treatment with teriparatide. Change in total hip BMD did not
show a statistically signiﬁcant difference between groups. Our
results support previous ﬁndings by Kobayashi and col-
leagues(53) who described a greater increase in lumbar spine
BMD with teriparatide at 48 weeks postsurgery compared with
alendronate, in non-osteoporotic patients from Japan who were
partially immobilized after total hip arthroplasty.
Although the current study was not powered to demonstrate
a reduction in the rates of new fracture andmortality, the higher
increase in BMD observed in the teriparatide-treated group
might have clinical relevance because it has been demonstrated
Fig. 5. Assessment of functional mobility: time to complete the TUG test (FASa). aMMRM analysis (with log-transformation); predeﬁned variables in the full
model included treatment, visit, treatment-by-visit interaction, age, type of fracture (31-A1, 31-A2), type of reduction, type of walking aid, recall SF-36
physical component score, and baseline Charnley hip pain score. FAS¼ full analysis set; LS¼ least squares; SF-36¼ Short Form-36; TUG¼ timedup-and-go.
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that after an initial fragility fracture, the rate of subsequent
mortality increases with declining BMD.(5)
The BMD increases we observed were similar to those
reported in non-immobilized patients with severe osteoporosis
in the pivotal Phase 3 trials of risedronate(54,55) and teripara-
tide.(24) The exception was the effect of risedronate on femoral
neck BMD at 78 weeks in our study (–1.19%) compared with the
þ1.5% to þ2% increase observed at 18 months of treatment in
the pivotal phase 3 trials.(54,55) The reason for this discrepancy is
unclear, but it should be considered that patients with a recent
hip fracture show a decline in the contralateral unfractured
femoral neck BMD of approximately 5% compared to baseline
after 12 months of follow-up.(13,14,16) Therefore, risedronate was
likely able to stop this quick and profound decline in BMD,
although less effectively than teriparatide. Interestingly, previ-
ous results in 239 patients with a recent hip fracture treated with
weekly alendronate for 12 months also showed a lower than
expected increase in femoral neck BMD compared with that in
the phase 3 pivotal trials in women with postmenopausal
osteoporosis.(56) The authors hypothesize on the potential
impact of changes in bone volume and/or a negative effect of
the relative lack of weight-bearing exercise.(56) This hypothesis
was also suggested by Lee and colleagues(57) who observed that
53.7% of the patients treated with alendronate showed a
decline in lumbar spine volumetric BMD, 1 year after a total
knee arthroplasty. In another series of patients with lower leg






(n¼ 216) Fischer’s p value
Treatment emergent adverse events, n (%)
Any 59 (55.7) 58 (52.7) 117 (54.2) 0.684
Leading to discontinuation 5 (4.7) 6 (5.5) 11 (5.1) 1.000
Serious 21 (19.8) 27 (24.5) 48 (22.2) 0.418
Leading to hospitalization 19 (17.9) 20 (18.2) 39 (18.1) 1.000
Death 2 (1.9) 7 (6.4) 9 (4.2) 0.171
Clinical fractures
Patients with 1 clinical vertebral fracture, n (%) 0 1 (0.9) 1 (0.5) 1.000
Patients with 1 clinical nonvertebral fracture,
n (%)
5 (4.7) 10 (9.1) 15 (6.9) 0.286
Number of fractures, n 5 12 17 0.099a
Hip 2 7 9
Humerus 1 1 2
Pelvis 0 2 2
Laboratory parameters
Serum 25OHD, pmol/mL
Week 26 n¼ 62 n¼ 66
Mean SD 62.16 16.4 71.29 20.3 0.006
Week 78 n¼ 55 n¼ 57
Mean SD 59.47 18.6 68.35 24.4 0.032
Serum alkaline phosphatase, IU/L
Week 26 n¼ 62 n¼ 64
Mean SD 95.74 29.3 83.61 21.9 0.010
Week 78 n¼ 55 n¼ 56
Mean SD 88.91 26.0 74.52 20.7 0.002
Hypercalcemiab
Week 6 n¼ 81 n¼ 78
n (%) 7 (7.4) 5 (5.1) 0.766
Week 26 n¼ 62 n¼ 62
n (%) 8 (12.9) 1 (1.5) 0.032
Week 78 n¼ 55 n¼ 55
n (%) 3 (5.3) 0 (0) 0.243
Hyperuricemiac
Week 6 n¼ 82 n¼ 79
n (%) 13 (15.9) 4 (5.1) 0.038
Week 26 n¼ 62 n¼ 64
n (%) 9 (14.5) 6 (9.4) 0.420
Week 78 n¼ 55 n¼ 56
n (%) 8 (14.5) 7 (12.5) 0.788
Percentages are based on number of patients with nonmissing values. Safety analyses included all patients receiving at least 1 dose of study
medication (active or placebo dummy).
aPoisson regression.
bAlbumin corrected serum calcium >10.6mg/dL
cSerum uric acid >8.3mg/dL in men and >7.5mg/dL in women.
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fractures who received daily alendronate, femoral neck BMDwas
almost unchanged compared to baseline after 12 months of
follow-up, although this bisphosphonate mitigated the 5%
reduction in femoral neck BMD observed in the placebo-treated
group.(11) Finally, in the HORIZON Recurrent Fracture Trial, BMD
at the femoral neck increased by þ0.8% and þ2.2% at 12 and
24 months of treatment with zoledronic acid, respectively.(21)
However, these increases are lower than those described in the
pivotal trial in women with postmenopausal osteoporosis
(þ2.5% and þ3.5% at 12 and 24 months, respectively).(58)
The safety proﬁles of teriparatide and risedronate observed in
our study were according to the prescribing information, with
no new safety signals identiﬁed, and with no change in the
beneﬁt-risk assessments of these treatments in this elderly
population of patients with low bone mass and a recent hip
fracture. Patients in the teriparatide group showed a statistically
signiﬁcant increase in hyperuricemia at 6 weeks (15.9%) and
hypercalcemia at 26 weeks (12.9%) of treatment versus
risedronate, but these were relatively mild and without clinical
complications. Both treatments showed similar frequencies of
loss of reduction (2 cases [3.2%] with teriparatide and 4 cases
[6.5%] with risedronate) and mechanical failure of the implant
with only one case of screw cutout per treatment group, and no
case of non-union. Our results support previouswork by Kim and
colleagues(59) who showed that the early administration of
risedronate does not appear to affect the rate of healing of an
intertrochanteric, osteoporotic fracture or the incidence of
complications. Our ﬁndings are also similar to those in the study
by Kim and colleagues(59) in patients who started oral weekly
risedronate 1 week after surgery, where all fractures were
radiologically healed by 20 weeks after surgery.
The overall incidence of clinical fracture rates remained
relatively low, with a numerically, nonstatistically signiﬁcant
lower risk of nonvertebral fractures in the teriparatide
group.
In this study, we also analyzed the effects of the two study
drugs on several aspects of fracture recovery, either as
secondary or exploratory objectives. Because healing and
recovery of a hip fracture are normally completed in approxi-
mately 6 months, the study was designed as double-dummy,
placebo-controlled during the ﬁrst 26 weeks after randomiza-
tion, with the aim of avoiding potential, subjective patient-
related outcomes bias. The results of the primary analysis of
these endpoints were previously published.(33) In the current
report, we extended the analysis of these recovery endpoints to
the full 78 weeks of treatment. During the last 52 weeks of
treatment, the time required to complete the TUG test and
VAS-assessed hip pain during the TUG test—which showed a
reduction in the early recovery phase—were no longer
signiﬁcantly different between the two groups, probably
reﬂecting the successful completion of the fracture healing
process in the patients remaining in the study. The slight
expected differences in the TUG test and hip pain results
between the 26-week analyses reported by Aspenberg and
colleagues(33) and this work may be attributed to the statistical
methodology (MMRM) and the additional time points at 52
and 78 weeks included in the MMRM models. The analysis of
data from the full treatment period conﬁrmed the lack of
statistically signiﬁcant difference between treatments for the
patient-rated health status by the SF-36 survey, ability towalk, or
the Charnley hip pain score.
Although preclinical studies using PTH in animal models are
promising(60–65) and proof-of-concept clinical trials(66,67) and
sporadic case reports in humans(68,69) showed an anecdotal
beneﬁt of teriparatide in various fractures, to date there are no
well-controlled clinical trials to support the hypothesis that
teriparatide improves fracture healing. Huang and col-
leagues(70) have recently reported that 6 months of teripara-
tide was associated with faster fracture healing, better quality
of life, and lower frequency of lag screw cutout and mortality
Fig. 6. Evaluation of self-reported hip pain during the TUG test: 100mm VAS (FASa). aMMRM analysis; predeﬁned variables in the full model included
treatment, visit, treatment-by-visit interaction, type of fracture, type of reduction, adequacy of reduction, use of opioids, and use of nonsteroidal anti-
inﬂammatory drugs. bLower conﬁdence interval crosses zero for teriparatide. FAS¼ full analysis set; LS¼ least squares; TUG¼ timed up-and-go test;
VAS¼Visual Analog Scale.
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rates in 189 patients with intertrochanteric fractures. Our
ﬁndings did not support the results of that retrospective study,
but it should be stressed that our study was not powered for
any fracture recovery or healing outcomes. A recent report of
the effects of teriparatide versus placebo on fracture healing
after internal ﬁxation of a femoral neck fracture failed to detect
any signiﬁcant differences between treatment groups due to
the small sample size (n¼ 78 in the teriparatide group and
n¼ 81 in the placebo group). This clinical program had to be
stopped early because accrual in both studies was much
slower than expected given the difﬁculty in enrolling patients
for this kind of study.(71)
Our study had some limitations. We had strict eligibility
criteria and relied on the willingness of patients and their
caregivers for participation in the study. Consequently, only
10% of the patients admitted with pertrochanteric hip
fractures in the study centers were enrolled. This may have
created a selection bias toward a younger and healthier
population, thereby limiting the external validity of the study
results in more deteriorated patients with comorbidities such
as dementia or a history of malignancy. However, we believe
patients in our study were not that healthy, given the long
average time required by them to complete the TUG test even
at Week 78; a TUG score >13.5 s is used to identify individuals
with a high risk of falling in the community setting.(72,73) Low
enrolment rates of 6.3% and 4.0% were also observed in other
randomized studies evaluating the effect of anti-osteoporotic
medications for hip fracture healing,(74,75) thus underscoring
the challenges of recruiting and retaining elderly patients in
such studies. We had a high dropout rate and relative low
compliance with visit dates and study procedures. This is not
unexpected in frail, elderly patients with a severe fracture, and
stresses the difﬁculties of performing randomized clinical trials
involving frequent, cumbersome postoperative assessments in
elderly patients with fractures who have substantial transpor-
tation issues. The attempted clinical trial by Kanakaris and
colleagues(74) clearly showed that it is very difﬁcult to
complete a prospective randomized study aiming to identify
and compare the effect of different anti-osteoporotic drugs
administered at the time of healing of fragility hip fractures,
with the desired sample size and stringent recruitment criteria.
The sample size of this study was not large enough to detect a
difference in fracture rates between treatments. Rates of
incident clinical fractures were prospectively collected as
safety-related endpoints. Furthermore, it is likely that we
underestimated the incidence of new vertebral fractures
because we did not evaluate spinal radiographs unless
patients developed symptoms of a possible vertebral fracture.
This study has several strengths. To the best of our
knowledge, this is the ﬁrst well-controlled study of imaging
and clinical outcomes with a systemically active biologic drug
in patients with a hip fracture, using an active comparator in a
double-dummy design during the ﬁrst 26 weeks of follow-up.
The study was performed with a rigorous methodological
design, a predeﬁned statistical analysis plan, and using
validated instruments to measure functional outcomes and
pain. Hip X-rays and BMD scans were evaluated by central,
blinded reviewers using prespeciﬁed adjudication criteria,
widely accepted in the literature. Biases arising from subjective
patient-reported outcomes were avoided through a double-
dummy design and complete blinding during the 26-week
fracture recovery phase. Patients were eligible for participation
regardless of prior anti-osteoporotic drug use. Finally,
treatment compliance with both drugs was very high,
probably reﬂecting the experimental framework of a clinical
trial.
In conclusion, teriparatide treatment during a 78-week period
was associatedwith a signiﬁcantly greater increase in BMD at the
lumbar spine and femoral neck, and a signiﬁcantly shorter time
to complete the TUG test compared with risedronate, in elderly
patients with a recent pertrochanteric hip fracture. We did not
observe any signs suggesting that these drugs were unsafe
when used immediately after fracture repair. Further studies are
warranted to investigate whether these observations in the early
recovery phase translate into reduction of subsequent fragility
fractures and premature mortality rates.
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